Novel Radionuclides for Nuclear Medicine – Current Perspective from Clinical End Users’ Point of View in Europe

  • Saule, L. (Speaker)
  • Radziņa, M. (Co-author)
  • Edgars Mamis (Co-author)
  • Elina Pajuste (Co-author)
  • Thomas Cocolios (Co-author)
  • Zeynep Talip (Co-author)
  • Thierry Stora (Co-author)
  • Ulli Koester (Co-author)
  • Mikael Jenssen (Co-author)
  • Kirsten Leufgen (Co-author)

Activity: Talk or presentation types › Poster presentation

Description

Novel radionuclides for nuclear medicine can improve diagnostics of a broad spectrum of diseases. Moreover, achievements in theranostic (therapy + diagnostic) can lead to precision and quick way from diagnosis to treatment. Theranostics is a treatment using diagnostic imaging to identify if target receptors are present on cancer cells, followed by precision radiation treatment that targets these receptors. In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of innovative radionuclides for medical research..A consortium questionnaire was created and disseminated through the PRISMAP community, professional associations of radiology and nuclear medicine and preclinical/clinical end users in Europe. The current status and needs of clinical end-users in nuclear medicine were identified. . A total of 40 preclinical/clinical users institutions took part in the survey (55% clinical hospitals, 25% research institution-hospital collaborations, 10% preclinical research institutions, 2,5% private clinics and 7,5% - other types). Respondents were from 22 countries. All respondents performed studies in oncology(100%), while inflammation studies were reported from 80% of respondents, cardiology - 77,5% respondents, neurology - 75% respondents. A similar scene was seen about studies which respondent’s facility plan to implement within the next 2-5 years.  Clinical end users currently use the following non-conventional radionuclides in their studies: 177Lu(80%), 68Ga(72,5%), 111In(57,5%), 90Y(52,5%), other alpha emitters(42,5%), 225Ac(20%), 64Cu(15%) and Terbium isotopes(10%). Radionuclides that would be of interest for use within the next 2-5 years are 64Cu(50%), Terbium radionuclide “family”(37%) and alpha emitters, such as 225Ac(67%) which is width used both in diagnostics and radionuclide therapy.. The current perspective shows that nuclear medicine specialists/radiologists from broad parts of Europe are interested not only in new radionuclides for diagnostics, but also in therapy and technology advancements that confirm their interest in development.
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational

Related content